Enliven Therapeutics, Inc.·4

Aug 11, 6:51 PM ET

Patel Anish 4

4 · Enliven Therapeutics, Inc. · Filed Aug 11, 2025

Insider Transaction Report

Form 4
Period: 2025-08-07
Patel Anish
CHIEF OPERATING OFFICER
Transactions
  • Sale

    Common Stock

    2025-08-07$18.20/sh6,262$113,949290,380 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-08-07$18.93/sh405$7,667289,975 total(indirect: See footnote)
Footnotes (4)
  • [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").
  • [F2]This transaction was executed in multiple trades at prices ranging from $17.78 to $18.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F3]The shares are held by The Patel / Dong Family Trust.
  • [F4]This transaction was executed in multiple trades at prices ranging from $18.805 to $19.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Documents

1 file
  • 4
    form4-08112025_100829.xmlPrimary